Clinical Trials Browser

Approved for marketing × Liver Neoplasms × Clear all

NCT00906984 2024-01-08

TheraSphere

Approved for marketing

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01076517 2021-04-01

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Approved for marketing

Gastrointestinal

Liver Neoplasms